Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

著者: Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen, Elias Jabbour, Partow Kebriaei, Michael Rytting, Sergernne York, Farhad Ravandi, Monica Kwari, Stefan Faderl, Mary Beth Rios, Jörge E. Cortes, Luis Fayad, Robert Tarnai, Sa A. Wang, Richard Champlin, Anjali S. Advani, Susan O’Brien - The Lancet 2012 被引用: 412